Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre
Caroline Zöllner, Jörg Hofmann, K. Lutz, Frank Tacke, Münevver Demir
Abstract
In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n = 7 male, n = 1 female; n = 3 compensated cirrhosis) treated at our centre. Median ALT values declined from 82 to 34 U/L after 48 weeks. Median HDV RNA dropped from 13 380 000 to 3135 copies/ml. One patient showed no significant response and was discontinued at week 16. Overall, we observed a favourable safety profile and a marked biochemical and virological response in the majority of our patients.
Topics & Concepts
MedicineCirrhosisHEPATITIS DELTAInternal medicineHepatitis DAntiviral therapyEuropean unionGastroenterologyChronic hepatitisVirusVirologySurgeryHepatitis B virusHBsAgEconomic policyBusinessHepatitis C virus researchHepatitis B Virus StudiesHepatitis Viruses Studies and Epidemiology